Yu Jing, Yan Yunmeng, Hua Chunlan, Ming Liang
Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University.
Department of Clinical Laboratory, Key Clinical Laboratory of Henan Province, Zhengzhou, China.
Medicine (Baltimore). 2019 Apr;98(16):e15196. doi: 10.1097/MD.0000000000015196.
Accumulating evidence suggested that the expression level of long noncoding RNA small nucleolar RNA host gene 1 (lncRNA SNHG1) was upregulated in various cancers, and high expression of SNHG1 was associated with metastasis and prognosis in patients with cancer.The relationship between SNHG1 expression and metastasis or prognosis in malignant tumors was investigated in this meta-analysis.
A systematic search was performed in PubMed, Web of Science, and Cochrane Library from inception until May 31, 2018. Hazard ratio (HR) or odds ratio (OR) with 95% confidence intervals (95% CIs) were calculated to demonstrate prognostic value of SNHG1 using Stata 12.0 software.
A total of 10 studies including 1129 patients were finally enrolled in the meta-analysis based on the inclusion and exclusion criteria. Increased SNHG1 expression was significantly associated with lymph node metastasis (OR = 3.28, 95% CI = 2.02-5.33) and advanced TNM stage (OR = 0.26, 95% CI = 0.16-0.43). Moreover, high expression of SNHG1 could predict poor overall survival (HR = 2.32, 95% CI = 1.90-2.83), event-free survival (HR = 1.58, 95% CI = 1.06-2.35), recurrence-free survival (HR = 2.15, 95% CI = 1.23-3.77), progression-free survival (HR = 2.75, 95% CI = 1.70-4.46), and disease-free survival (HR = 1.93, 95% CI = 1.10-3.40) in patients with cancer.
The present meta-analysis demonstrated that upregulation of lncRNA SNHG1 might serve as a useful prognostic biomarker in various cancers.
越来越多的证据表明，长链非编码RNA小核仁RNA宿主基因1（lncRNA SNHG1）在多种癌症中的表达水平上调，且SNHG1的高表达与癌症患者的转移及预后相关。本荟萃分析旨在研究SNHG1表达与恶性肿瘤转移或预后之间的关系。
对PubMed、Web of Science和Cochrane图书馆进行系统检索，检索时间从建库至2018年5月31日。使用Stata 12.0软件计算风险比（HR）或比值比（OR）及95%置信区间（95%CI），以证明SNHG1的预后价值。
根据纳入和排除标准，共有10项研究（包含1129例患者）最终纳入本荟萃分析。SNHG1表达增加与淋巴结转移（OR = 3.28，95%CI = 2.02 - 5.33）及晚期TNM分期（OR = 0.26，95%CI = 0.16 - 0.43）显著相关。此外，SNHG1的高表达可预测癌症患者较差的总生存期（HR = 2.32，95%CI = 1.90 - 2.83）、无事件生存期（HR = 1.58，95%CI = 1.06 - 2.35）、无复发生存期（HR = 2.15，95%CI = 1.23 - 3.77）、无进展生存期（HR = 2.75，95%CI = 1.70 - 4.46）及无病生存期（HR = 1.93，95%CI = 1.10 - 3.40）。
本荟萃分析表明，lncRNA SNHG1的上调可能是多种癌症中一种有用的预后生物标志物。
